New Insight with Dr. Veeral Sheth

Diabetes Dialogue

Don’t Miss a Beat

Crisis Point

Larry Ereshefsky, PharmD: Brilaroxazine Improves Schizophrenia Symptoms

 at 50 mg and 15 mg significantly reduced symptoms of acute

The pivotal RECOVER trial was led by Laxminarayan Bhag, from Reviva Pharmaceuticals, to assess the safety and efficacy of brilaroxazine: a serotonin-dopamine system modulator targeting D2/3/4 and 5-HT1A/2A receptors as a partial agonist and 5-HT2B/7 receptors as an antagonist.

Brilaroxazine controls inflammatory cytokines, a potential disease driver. The primary endpoint of improvement in the PANSS score from baseline to day 28, compared with placebo.

Participants on brilaroxazine 50 mg achieved a 10.1-point reduction compared to placebo (-23.9 vs -13.8; P < .001). Investigators observed significant reductions in positive, negative, and negative marder symptoms, as well as PANSS social cognition, excitement or agitation, PSP, and CGI-S. Brilaroxazine 15 mg was placebo to placebo for all endpoints.

, Larry Ereshefsky, PharmD, the chief scientific officer at CenExcel Research and Follow the Molecule, discussed the RECOVER trial, from how brilaroxazine improves various symptom domains of schizophrenia to the drug’s safety profile.

When asked if brilaroxazine brought any notable adverse events, Ereshefsky responded, "The fascinating part is if they’re not notable.” He continued by saying how “remarkable” the safety profile was, with an all-cause discontinuation rate of 16%. During the phase 3 trial, the number of patients discontinuing the trial due to treatment-emergent adverse events was 0.

Some adverse events were sedation and restlessness, which was all depending on a participant’s sensitivity to the drug.

“That's why you need multiple doses for this drug,” Ereshefsky said. “I'm not a believer, that one dose fits everybody.”

He also dived into the effects of brilaroxazine on inflammatory cytokines and neuroinflammation and how this can impact future treatment strategies. Every single psychotic episode damages the brain, shrinking the tissue. He said if future studies continue to show promise, this drug could potentially prevent the brain damage that occurs in schizophrenia, particularly in early treatment.

“Long term, changing the inflammatory system…could be a game changer,” Ereshefsky said. “It’s a little bit tangential, but it illustrates how different this drug seems to be from others.”

Investigators are considering examining the drug for the treatment of psoriasis, pulmonary disease, hypertension, fibrotic illness—all of which have nothing to do with schizophrenia.

“Yet this drug seems to have a signal here, so that that's a story still unfolding, but it is something that could differentiate,” Ereshefsky said.

Derman, C. Phase 3 Data on Brilaroxazine for Schizophrenia with Larry Ereshefsky, PharmD. HCPLive. April 24, 2024. 

https://www.hcplive.com/view/phase-3-data-on-brilaroxazine-for-schizophrenia-with-larry-ereshefsky-pharmd

Bhat, L, Bhat, S, Ramakrishnan, A. Brilaroxazine Efficacy and Safety in the Phase 3 RECOVER Trial in Acute Schizophrenia. ASCPT Annual Conference in Colorado Springs, USA on March 27 – 29, 2024.


Videos

Larry Ereshefsky, PharmD, discussed the effects of brilaroxazine on inflammatory cytokines and neuroinflammation and how this can impact future schizophrenia treatment.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Schizophrenia

The HCPLive schizophrenia page is a resource for medical news and expert insights on the mental disorder. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for schizophrenia, and more.

Connor Iapoce is an associate editor for 

 and joined the MJH Life Sciences team in April 2021. He graduated from The College of New Jersey with a degree in Journalism and Professional Writing. He enjoys listening to records, going to concerts, and playing with his cat Squish. You can reach him at 

A new analysis identified a significant lapse in 

 care over 2 years, with the most disadvantaged neighborhoods demonstrating an interaction with race and ethnicity.

Non-Hispanic White patients from areas of socioeconomic disadvantage were more likely to have lapses in diabetic retinopathy care, compared with those from less disadvantaged neighborhoods. 

Meanwhile, non-Hispanic Black and Hispanic patients from nearly all examined neighborhoods exhibited a greater risk of experiencing lapses in care, compared with non-Hispanic White patients from the least socioeconomically disadvantaged areas.

“For racial and ethnic minority groups, the impacts of structural racism and its downstream effects on the maldistribution of individual-level resources may compound the adverse outcomes associated with neighborhood socioeconomic disadvantage,” wrote the investigative team, led by Cindy X. Cai, MD, Wilmer Eye Institute, Johns Hopkins School of Medicine.

Health outcomes correlate with SDOH, with individual- and neighbor-level criteria influencing the roles of diabetic retinopathy screening.

 Minority populations are known to experience poorer health outcomes because of these neighborhood socioeconomic disadvantages, ranging from lack of access to care, food deserts, or environmental hazards.

This retrospective cohort study investigated whether the association of neighborhood-level SDOH with the threat of lapses in care for diabetic retinopathy was altered by race and ethnicity.

 Adults with diabetes were observed at the investigator’s institution from 2013 to 2022 for diabetic retinopathy screening or treatment. The analysis outcomes were lapses in diabetic retinopathy care over 2 years.

Primary exposures were the patient neighborhood socioeconomic disadvantage, determined using the 2019 area deprivation index (ADI)—divided into quartiles, Q4 represented those at the most socioeconomic disadvantage. The electronic health record was used to extra baseline characteristics, such as race and ethnicity, other demographic data, clinic, residential distance from clinic, severity of diabetic retinopathy, other retinal disorders, and glaucoma.

For the analysis, multivariable logistic regression models were created to evaluate the association between ADI quartile and lapses in care, after adjusting for baseline characteristics. Across 36,487 patients, 63% had a lapse in care, including 60% in ADI Q1, 62% in Q2, 66% in Q3, and 68% in Q4.

Cai and colleagues identified an interaction between ADI and race and ethnicity (

 = .005). In particular, non-Hispanic White patients from areas of more socioeconomic disadvantage experienced an increased risk of lapses in care.

Pairwise comparisons were performed using contrast coefficients adjusted with Bonferroni correction. In the pairwise comparisons, non-Hispanic Black, and Hispanic patients, as well as patients with other races and ethnicities, from high ADI quartiles exhibited a greater likelihood of lapses in care, compared with non-Hispanic White patients in Q1 and Q2. Particularly, non-Hispanic Black patients from Q1 showed lower odds of care lapses, compared with non-Hispanic White patients from Q4.

Overall, Cai and colleagues indicated place and race “clearly matter” regarding lapses in diabetic retinopathy care. Areas with socioeconomic disadvantage can display factors, including concentrated poverty, issues with walkability, limited access to public transportation, and lack of health care access, that make follow-up to eye care challenging for patients.

“Given that health and health behaviors represent a complex interplay among individual, community, and societal factors, future studies of diabetic retinopathy care should consider individual and neighborhood-level SDOH and their interactions toward the goal of informing public policies to eliminate disparities in vision health,” they wrote.

Tang T, Tran D, Han D, Zeger SL, Crews DC, Cai CX. Place, Race, and Lapses in Diabetic Retinopathy Care. 

 Published online April 25, 2024. doi:10.1001/jamaophthalmol.2024.0974

Gaskin DJ, Thorpe RJ Jr, McGinty EE, et al. Disparities in diabetes: the nexus of race, poverty, and place. 

. 2014;104(11):2147-2155. doi:10.2105/AJPH.2013.301420

Yusuf R, Chen EM, Nwanyanwu K, Richards B. Neighborhood Deprivation and Adherence to Initial Diabetic Retinopathy Screening. 

. 2020;4(5):550-552. doi:10.1016/j.oret.2020.01.016

Articles

Areas with socioeconomic disadvantage often face concentrated poverty, poor walkability, and few healthcare facilities, creating challenges in eye care follow-up.

Ophthalmology

Ophthalmology page, resources on the topics of medical news and expert insight into ophthalmic disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on eye disease research, treatment, and drug development.

Diabetic Macular Edema

The HCPLive diabetic macular edema page is a comprehensive resource for clinical news and insights on DME. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for the leading cause of blindness, and more.

Race, Neighborhood Influence Lapses in Diabetic Retinopathy Care 

Lana Pine is the editor of HCPLive Rheumatology. She is an experienced editor and technical writer with a demonstrated history of working in the banking and publishing industries. In her free time, she enjoys cooking, yoga, listening to podcasts, and drawing. She can be reached via email at LPine@mjhlifesciences.com.

Recent research demonstrated transient elastography was a reliable and superior method to detect liver fibrosis among a cohort of Chinese patients with 

 being treated with methotrexate compared with the total cumulative dose of methotrexate (≥ 3.5 g) method.

Therefore, a liver biopsy should be reserved for high-risk patients or those with liver stiffness of ≥ 11.7 kilopascals (kPa) on transient elastography, according to a study published in the 

Although methotrexate is an effective, safe, and cost-effective immunosuppressive drug for patients with PsO and 

, prolonged use may cause liver fibrosis and fatty changes without altering liver enzymes. These changes might be due to the production of extracellular adenosine.

 As liver biopsy—a gold standard for detecting liver injury among this patient population—is risky and invasive, transient elastography could be a safer option.

“Transient elastography is a non-invasive method for assessing liver ‘hardness’ or stiffness that involves measuring the velocity of a vibration wave (ie, a shear wave) when travelling to a particular depth inside the liver, based on the principle that the wave velocity is greater in fibrotic tissue than in normal liver tissue,” wrote a group of international investigators predominantly associated with the University of Hong Kong. “This technique has been used as a screening tool for liver cirrhosis in various conditions. In contrast to liver biopsy, transient elastography allows the simultaneous assessment of a larger sampling area, is easily reproducible, and has low inter-observer variability and a low failure rate (<5%).”

Investigators evaluated the performance of transient elastography in methotrexate-induced liver fibrosis compared with liver biopsy in a cohort of adult Chinese patients with clinically diagnosed PsO. Liver stiffness was measured using transient elastography. Exclusion criteria included conditions that could influence transient elastography performance, positive viral hepatitis carrier status, and known liver cirrhosis. Biopsy was conducted when liver stiffness was ≥ 7.1 kPa or if the total cumulative dose of methotrexate was ≥ 3.5 g.

A total of 228 patients were ultimately recruited for the study, of which 34 met the inclusion criteria. Of these, approximately one-fourth (26.5%) had significant liver fibrosis. The area under the receiver operating characteristic curve was .76 (95% confidence interval [CI] = .59 — .93; 

= .021), which demonstrated the satisfactory performance of transient elastography in detecting liver fibrosis.

Using a cut-off value of 7.1 kPA for liver stiffness, results yielded 100% sensitivity and 68% specificity among this patient population. Although liver fibrosis was significantly correlated with obesity and diabetes status, as defined by a body mass index of ≥ 30 kg/m2, waist circumference ≥ 138 cm, and glycated hemoglobin level ≥ 7.8%, it was not linked with the total cumulative dose of methotrexate or the duration of methotrexate use.

Investigators noted the small sample size as a limitation of the study. A larger sample size could be beneficial to draw definitive conclusions, despite liver fibrosis being generally uncommon in patients with PsO receiving methotrexate.

“When considering liver biopsy to rule out the possibility of clinically significant liver fibrosis, transient elastography-based liver stiffness measurements provide superior reference information, compared with the total cumulative dose of methotrexate,” investigators concluded. “Patients with high body mass index, body weight, and abdominal obesity have a higher risk of liver fibrosis. Therefore, these factors should be considered when monitoring methotrexate-related liver fibrosis in psoriasis patients.”

Wong CSM, Mak LLY, Lee VKH, et al. Detection of significant liver fibrosis in Chinese psoriasis patients receiving methotrexate: a comparison between transient elastography and liver histology. 

. 2024;30(2):110-119. doi:10.12809/hkmj2210364

Themido R, Loureiro M, Pecegueiro M, Brandão M, Campos MC. Methotrexate hepatotoxicity in psoriatic patients submitted to long-term therapy. Acta Derm Venereol 1992;72:361-4

Using a cut-off value of 7.1 kPA for liver stiffness, results of the transient elastography yielded 100% sensitivity and 68% specificity among this patient population. 

Psoriatic Arthritis

On the HCPLive psoriatic arthritis page, resources on the topics of medical news and expert insight into PsA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on arthritis, and more.

Transient Elastography Deemed Reliable Method to Detect Liver Fibrosis in Patients with PsO Treated with MTX

Patrick Campbell is the managing editor of HCPLive. Formerly the editorial lead of Endocrinology Network, Practical Cardiology, and Rheumatology Network, Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. He now helps to lead coverage in each of these respective areas for HCPLive. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter with the Pocono Record in Stroudsburg, PA, and Star News Group in Manasquan, NJ. He also touts experience in multimedia, having spent time as a multimedia specialist with NJ Advance Media and multimedia coordinator at the Pocono Record. Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

New data from a trio of studies presented at the 

American College of Cardiology 2024 (ACC.24) Annual Scientific Session

 are offering insight into the benefits and risks of intensive blood pressure targeting based on systematic reviews and meta-analyses of randomized controlled trial data.

“There's really a lot of a lot of variability among these different studies. But like I said, when we excluded some of the trials, there was a statistically significant reduction in all-cause mortality and there was reduction in non-fatal stroke that we found as well. So, I think that there isn't a one size fits all approach for every single patient as far as intensive versus standard blood pressure control,” explained study investigator Matthew Nudy, MD, assistant professor of Medicine and Public Health Sciences at Penn State College of Medicine. “I think there are a lot of factors that need to be taken into account, like age of the patient, how frail is the patient? Is the patient experiencing polypharmacy? And are there any adherence issues to medications? So, I think there really needs to be like an individualized approach to intensive blood pressure control for patients.”

Intensive Blood Pressure Control and Nonfatal Myocardial Infarction

A systematic review and meta-analysis of 9 randomized controlled trials, the investigators’ study into the effects of intensive blood pressure control on nonfatal myocardial infarction included data from 25,524 participants. These individuals had a mean age of 66.9 (Standard Deviation [SD], 7.0) years, 43.9% were female, and the mean follow-up time was 3.8 years.

The primary outcome of interest of the study was the risk ratio (RR) for non-fatal myocardial infarction associated with intensive blood pressure control relative to standard blood pressure control.

Upon analysis, results indicated use of intensive blood pressure control did not significantly reduce the risk of non-fatal myocardial infarction among participants (7.5 vs 8.4 events per 1000 patient-years; RR 0.89; 95% CI 0.76 to 1.03; I2 = 0.00), with this effect not sensitive to the exclusion of any individual trial and not in correlation with any of the regressor variables tested by investigators.

Intensive Blood Pressure Control and Nonfatal Stroke

The systematic review and meta-analysis examining the effect of intensive blood pressure control on nonfatal stroke also featured 9 randomized controlled trials. These studies provided investigators with a cohort of 32,924 for inclusion. These individuals had a mean age of 66.7 (SD, 7.0) years, 43.3% were female, and the mean follow-up time was 4.0 years.

Upon analysis, results indicated intensive blood pressure control was associated with significant reduction in nonfatal relative to standard control, with this treatment effect not sensitive to the exclusion of any individual trial. Investigators found exclusi0on of the JATOS trial reduced heterogeneity the most (I2 = 12.7), while meta-regression revealed a significant correlation favoring intensive blood pressure control as follow-up time increased (R2 = 1.00; regression coefficient -0.11; 

Intensive Blood Pressure Control and All-Cause Mortality

The largest of the 3 systematic reviews and meta-analyses presented by Nudy and colleagues at ACC.24 contained 19 randomized control trials evaluating the effects of intensive and standard blood pressure control on all-cause mortality. From these 19 trials, investigators obtained information related to 55,821 participants for inclusion in their analysis.

Upon analysis, results indicated intensive blood pressure control did not result in a significant reduction in all-cause mortality (9.5 vs 10.0 events per 1000 patient-years; RR, 0.90; 95% Confidence Interval [CI] CI 0.80-1.02; I2 = 32.6). Investigators pointed out this effect became statistically significant with the individual exclusion of the HOT and JATOS trials. In meta regression analyses, results suggested a significant correlation favoring intensive control as the baseline risk of all-cause mortality in the control group increased (R2 = 1.00; coefficient -0.01; 

For more on these studies, check out our interview with Nudy from the conference floor at ACC.24.

Matthew Nudy, MD: Balancing the Benefits and Risk of Intensive Blood Pressure Control

Bussa R, Nudy M, Ahmed M, et al. A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EFFECT OF INTENSIVE BLOOD PRESSURE CONTROL ON NONFATAL MYOCARDIAL INFARCTION. Presented at: American College of Cardiology (ACC.24) Annual Scientific Session. April 6 – 8, 2024. Atlanta, GA.

Bussa R, Nudy M, Ahmed M, et al. A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EFFECT OF INTENSIVE BLOOD PRESSURE CONTROL ON NONFATAL STROKE. Presented at: American College of Cardiology (ACC.24) Annual Scientific Session. April 6 – 8, 2024. Atlanta, GA.

Bussa R, Nudy M, Ahmed M, et al. A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EFFECT OF INTENSIVE BLOOD PRESSURE CONTROL ON ALL-CAUSE MORTALITY. Presented at: American College of Cardiology (ACC.24) Annual Scientific Session. April 6 – 8, 2024. Atlanta, GA.

Matthew Nudy, MD, discusses a trio of meta-analyses examining the effects of intensive blood pressure control on various targets. 

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

, a limited percentage of words (11%) focused on treatment adherence, according to a study published in 

 These findings also showed limited medication adherence coverage coupled with narrow strategies in online gout resource.

Gout adherence is classified into 2 categories—unintentional and intentional—defined as the process by which patients choose not to take their medication based on beliefs and perceptions about their condition or treatment. For example, certain patients may not take their medications based on adverse side effects, while other patients may not adhere to medication due to forgetting to take the drug, challenges regarding refills, or encountering logistical barriers such as travel.

“Recent studies have emphasized the significance of online health information seeking as a potential factor that can impact adherence to prescribed medications,” wrote a group of international investigators led by Yasaman Emad, PhD candidate associated with the Department of Psychological Medicine at the University of Auckland in New Zealand. “The way in which people with gout consume online health information can shape their beliefs surrounding their condition and medication use, ultimately impacting their behaviour and level of adherence to prescribed medications.”

Investigators believe improved adherence portrayal could help to effectively manage gout through comprehensive strategies and clear, easily understood information strategies.

An analysis of how medication adherence is addressed among online gout resources was performed using data from 6 countries. They evaluated how often adherence was referred to, the strategies to improve patient adherence, and the types of non-adherence that were targeted. The readability of adherence material was also assessed.

A total of 151 online gout resources from medical and health organizations were included from predominantly English-speaking countries. The analysis used coding for adherence-promoting strategies and non-adherence, and Flesch-Kinacid Reading Ease scores and word count were collected.

Of the websites included, 77 discussed medication adherence (51%), with results demonstrating intentional non-adherence was more prevalent than unintentional non-adherence. A total of 67 websites focused on different types of non-adherence, citing drug-specific concerns (50%), misconceptions regarding gout curability and medication necessity (16%), forgetfulness (16%), and other barriers (5%).

Strategies designed to promote medication adherence were found in only 1 out of 3 websites, with medication education being the most prevalent strategy (17%), followed by engagement from healthcare providers (13%), and memory aid strategies (6%).

Overall, about 11% of the words (89.27, standard deviation [SD] = 76.35) in the entire document were focused on medication adherence among this patient population. Difficult reading comprehension was reported in approximately one-fifth of adherence-related sites.

Investigators noted limitations including analyzing predominantly English-speaking countries, which may hinder generalizability to patient websites from other countries. Currently, there are no guidelines for what types of material on non-adherence should be focused on within patient websites, which could account for the variability in material. Future work should focus on this. Additionally, readability cannot indicate the quality or comprehensiveness of the information alone. Lastly, the study did not include an analysis of resources for healthcare providers including the management guidelines or reference texts. Future research should include an evaluation of gout management guidelines regarding adherence optimization recommendations.

“The study showed that around half of websites providing patient information on gout did not cover adherence or provide any strategies to help patients keep to their medication regimen,” investigators concluded. “Websites could also be improved with greater attention to unintentional factors such as forgetting and through improving readability to help patients with lower health literacy.”

Emad Y, Derksen C, Petrie KJ, Dalbeth N. A content analysis of medication adherence material in patient educational resources about gout. 

. 2024;8(2):rkae042. Published 2024 Mar 19. doi:10.1093/rap/rkae042

Penner LS, Armitage CJ, Thornley T et al.Non-adherence to medicines: not solved but solvable. J Health Serv Res Policy 2009;14:1–61.

Strategies designed to promote medication adherence were found in only 1 out of 3 websites. 

Gout

On the HCPLive gout page, resources on the topics of medical news and expert insight into gouty arthritis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on gout, and more.

Study Highlights Deficiencies in Medication Adherence Information, Strategies for Gout

FDA approves the generic equivalent of Narcan HCI Nasal Spray—naloxone hydrochloride (Naloxone HCI)—for an emergency treatment option for an opioid overdose.

FDA News

Addiction

Addiction medicine condition center page, resources on the topics of medical news and expert insight into clinical addiction can be found. Content includes articles, interviews, videos, podcasts, and breaking news on addiction therapy research, treatment, and drug development.

FDA Approves Over-the-Counter Naloxone Nasal Spray for Opioid Overdose

Tim Smith joined the MJH Life Sciences team as an assistant editor for HCPLive in August 2022. He graduated from UC Berkeley with a degree in political science, working in multimedia journalism as a staff writer prior to joining MJH. In his spare time, he enjoys reading, watching TV, listening to podcasts, and rock climbing. You can contact him at 

This analysis highlighted several trends in search volume regarding eczema, including correlations with weather and climate.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Atopic Dermatitis

Atopic Dermatitis condition center page, resources on the topics of medical news and expert insight into eczema can be found. Content includes articles, interviews, videos, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Study Highlights Trends in Atopic Dermatitis Web Search Volume in Europe

The extent of stigma significantly differs based on disease visibility and severity among children with chronic skin disorders.

Pediatrics

Pediatrics page, resources on the topics of medical news and expert insight into childhood health care can be found. Content includes articles, interviews, videos, podcasts, and breaking news on pediatric disease research, treatment, and drug development.

Pediatric Study Reveals Link Between Skin Disorder Visibility and Stigma

The second in our 3-part quiz series based on the NLA's 2024 update to their 2019 scientific statement on use of lipoprotein(a) in clinical practice focuses on recommendations for patients.

Dyslipidemia

Clinical Quiz: Lp(a) Recommendations for Patients from 2024 NLA Update on Use of Lipoprotein(a)

Eyenovia assessed the duration of effect of the lowest deliverable dose of tropicamide and phenylephrine hydrochloride ophthalmic spray 1%/2.5% in a phase 4 study.

Mydcombi Effective, Tolerable at Lowest Deliverable Dose for Mydriasis

New phase 3b/4 trial data compared both drugs efficacy and safety profiles for eczema patients, looking at adults and adolescents.

Upadacitinib Superior in Efficacy to Dupilumab for Atopic Dermatitis in Head-to-Head Study

Abigail Brooks is an assistant editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Tenofovir disoproxil fumarate was safe and effective for preventing mother-to-child transmission of HBV, but discontinuation was linked to postpartum hepatitis flares. 

Hepatology

Hepatitis C

Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.

Postpartum Hepatitis Flare Risk Increases After Discontinuation of Antiviral Therapy

A retrospective study challenges preoperative withholding of GLP-1 RAs in diabetes patients undergoing surgery, citing no increased risk of postoperative respiratory complications.

Type 2 Diabetes

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Surgery

The HCPLive surgery page is a resource for medical news and expert insights on invasive medicine. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for surgery, and more.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

GLP-1 Receptor Agonists Not Linked to Post-Op Respiratory Complications

Chun spoke in this interview segment about more recommendations for internal medicine physicians to give older adults related to aging, dementia, and statin use.

Audrey Chun, MD: Recommendations on Statins, Connecting Dementia to Hearing Loss

The fracture risk is greater for nursing home residents with dementia, greater baseline blood pressure values, and no recent antihypertensive medication use, a new study found.

Geriatrics

Geriatric medicine condition center page is a comprehensive resource for clinical news and insights on frequent geriatric-related diseases and conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for sleep disorder, dementia, Alzheimer's disease, and more.

Latest News

Larry Ereshefsky, PharmD: Brilaroxazine Improves Schizophrenia Symptoms

Race, Neighborhood Influence Lapses in Diabetic Retinopathy Care

Transient Elastography Deemed Reliable Method to Detect Liver Fibrosis in Patients with PsO Treated with MTX

Matthew Nudy, MD: Balancing the Benefits and Risk of Intensive Blood Pressure Control

Study Highlights Deficiencies in Medication Adherence Information, Strategies for Gout